Reading-headquartered medical products and technology company ConvaTec has added to its board with a new non-executive director appointment.
Dr Ros Rivaz has taken up her new position as a non-executive director of the company with immediate effect.
Her non-executive board experience spans FTSE 100, large private and not-for-profit organisations. Rivaz served as a non-executive director and chairman of the remuneration committee at Rexam prior to its acquisition by Ball Corporation in 2016, and currently sits on the board of RPC Group, Computacenter, Ministry of Defence Equipment and Support and is also vice chair of the council of Southampton University, among other roles.
Previously, Rivaz held a range of senior executive management roles across major FTSE100 and international businesses. From 2011 to 2014 she was global chief operating officer of Smith & Nephew, having previously served in senior operations, manufacturing and supply chain roles at Premier Foods, Diageo, ICI and Tate & Lyle.
Sir Christopher Gent, chairman of ConvaTec, said: “I am delighted to welcome Ros to the Board of ConvaTec. She brings exceptional and significant experience gained from a successful career across a variety of industries.
“Ros has a detailed understanding of the medical products and technology sector, and she will make a valuable contribution to ConvaTec. The board looks forward to working closely with her.”
Earlier this month, Nordic Capital and Avista agreed to sell 250 million shares in ConvaTec to institutional investors at a price of 322p per share, raising gross proceeds of £805m, through an accelerated bookbuilding process.
By Muhammad Aldalou
Source: Insider Media
After attending the annual Pulmonary Embolism Symposium last week in Austin, Texas, the analysts predicted clinical guidelines could shift toward catheter-based therapy once data from ongoing randomized trials is available.
SAS – the AI and analytics company – has been selected by AstraZeneca to help boost efficiency and drive automation in the delivery of statistical analyses for clinical and post-approval submissions to regulatory authorities.
After the Centers for Medicare & Medicaid Services (CMS) revealed the list of drugs set to face the first round of price negotiations under the Inflation Reduction Act (IRA), the drugmakers responsible for marketing them are confronting a series of deadlines.